Critical Reviews in Oncology / Hematology
Volume 78, Issue 3 , Pages 252-259 , June 2011

Comorbidity, not age, is prognostic in patients with advanced pancreatic cancer receiving gemcitabine-based chemotherapy

  • Yousuke Nakai

      Affiliations

    • Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan
    • ,
  • Hiroyuki Isayama

      Affiliations

    • Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan
    • Corresponding Author InformationCorresponding author at: Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo Bunkyo-ku, Tokyo 113-8655, Japan. Tel.: +81 3 3815 5411; fax: +81 3 3814 0021.
    • ,
  • Takashi Sasaki

      Affiliations

    • Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan
    • ,
  • Naoki Sasahira

      Affiliations

    • Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan
    • ,
  • Takeshi Tsujino

      Affiliations

    • Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan
    • ,
  • Hirofumi Kogure

      Affiliations

    • Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan
    • ,
  • Hiroshi Yagioka

      Affiliations

    • Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan
    • ,
  • Yoko Yashima

      Affiliations

    • Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan
    • ,
  • Osama Togawa

      Affiliations

    • Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan
    • ,
  • Toshihiko Arizumi

      Affiliations

    • Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan
    • ,
  • Saburo Matsubara

      Affiliations

    • Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan
    • ,
  • Kenji Hirano

      Affiliations

    • Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan
    • ,
  • Minoru Tada

      Affiliations

    • Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan
    • ,
  • Masao Omata

      Affiliations

    • Yamanashi Prefectural Hospital Organization, Japan
    • ,
  • Kazuhiko Koike

      Affiliations

    • Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan

,Accepted 28 May 2010.

References 

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225–249
  2. National Cancer Institute. SEER Cancer Statistics Review; 1975–2006. Available at http://seer.cancer.gov/csr/1975_2006/.
  3. Yip D, Karapetis C, Strickland A, Steer CB, Goldstein D. Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database Syst Rev. 2006;3:CD002093
  4. Hutchins LF, Unger JM, Crowley JJ, Coltman CA, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341(27):2061–2067
  5. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15(6):2403–2413
  6. Locher C, Fabre-Guillevin E, Brunetti F, et al. Fixed-dose rate gemcitabine in elderly patients with advanced pancreatic cancer: an observational study. Crit Rev Oncol Hematol. 2008;68(2):178–182
  7. Marechal R, Demols A, Gay F, et al. Tolerance and efficacy of gemcitabine and gemcitabine-based regimens in elderly patients with advanced pancreatic cancer. Pancreas. 2008;36(3):e16–e21
  8. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383
  9. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245–1251
  10. Extermann M, Overcash J, Lyman GH, Parr J, Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998;16(4):1582–1587
  11. Nakai Y, Isayama H, Sasaki T, et al. A pilot study for combination chemotherapy using gemcitabine and S-1 for advanced pancreatic cancer. Oncology. 2009;77(5):300–303
  12. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205–216
  13. Hardacre JM, Simo K, McGee MF, Stellato TA, Schulak JA. Pancreatic resection in octogenarians. J Surg Res. 2009;
  14. Davila JA, Chiao EY, Hasche JC, Petersen NJ, McGlynn KA, Shaib YH. Utilization and determinants of adjuvant therapy among older patients who receive curative surgery for pancreatic cancer. Pancreas. 2009;38(1):e18–e25
  15. Scurtu R, Bachellier P, Oussoultzoglou E, Rosso E, Maroni R, Jaeck D. Outcome after pancreaticoduodenectomy for cancer in elderly patients. J Gastrointest Surg. 2006;10(6):813–822
  16. Pallis AG, Polyzos A, Boukovinas I, et al. Pooled analysis of elderly patients with non-small cell lung cancer treated with front line docetaxel/gemcitabine regimen: the Hellenic Oncology Research Group experience. J Thorac Oncol. 2008;3(5):505–510
  17. Asmis TR, Ding K, Seymour L, et al. Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol. 2008;26(1):54–59
  18. Pasetto LM, Stefano T, Rossi E, Paris MK, Monfardini S. Treatment of stage IV colorectal carcinoma in elderly patients. Crit Rev Oncol Hematol. 2005;54(2):145–155
  19. Sastre J, Aranda E, Massuti B, et al. Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: comparative outcomes from the 03-TTD-01 phase III study. Crit Rev Oncol Hematol. 2009;70(2):134–144
  20. Jackson NA, Barrueco J, Soufi-Mahjoubi R, et al. Comparing safety and efficacy of first-line irinotecan/fluoropyrimidine combinations in elderly versus nonelderly patients with metastatic colorectal cancer: findings from the bolus, infusional, or capecitabine with camptostar-celecoxib study. Cancer. 2009;115(12):2617–2629
  21. Hanada K, Hino F, Amano H, Fukuda T, Kuroda Y. Current treatment strategies for pancreatic cancer in the elderly. Drugs Aging. 2006;23(5):403–410
  22. Aparicio T, Desrame J, Lecomte T, et al. Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly. Br J Cancer. 2003;89(8):1439–1444
  23. Aparicio T, Navazesh A, Boutron I, et al. Half of elderly patients routinely treated for colorectal cancer receive a sub-standard treatment. Crit Rev Oncol Hematol. 2009;71(3):249–257
  24. Firat S, Bousamra M, Gore E, Byhardt RW. Comorbidity and KPS are independent prognostic factors in stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2002;52(4):1047–1057
  25. Firat S, Byhardt RW, Gore E. Comorbidity and Karnofksy performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 2002;54(2):357–364

PII: S1040-8428(10)00139-3

doi: 10.1016/j.critrevonc.2010.05.007

Critical Reviews in Oncology / Hematology
Volume 78, Issue 3 , Pages 252-259 , June 2011

Article Tools

* Image Usage & Resolution